Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Change in Receivables (2016 - 2025)

Traws Pharma (TRAW) has disclosed Change in Receivables for 12 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For Q4 2025, Change in Receivables rose 606.46% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $2.0 million, up 671.55%, while the annual FY2025 figure was $2.0 million, 16.14% up from the prior year.
  • Change in Receivables hit $1.8 million in Q4 2025 for Traws Pharma, up from $668000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.8 million in Q4 2025 and bottomed at -$356000.0 in Q4 2024.
  • Average Change in Receivables over 5 years is $137666.7, with a median of -$1000.0 recorded in 2021.
  • Year-over-year, Change in Receivables crashed 1100.0% in 2023 and then skyrocketed 606.46% in 2025.
  • Traws Pharma's Change in Receivables stood at -$1000.0 in 2021, then changed by 0.0% to -$1000.0 in 2022, then skyrocketed by 200.0% to $1000.0 in 2023, then crashed by 35700.0% to -$356000.0 in 2024, then surged by 606.46% to $1.8 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $1.8 million, $668000.0, and -$331000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.